Antipyretic Treatment for Intrapartum Fever: Dipyrone vs Acetaminophen (RCT)

Launched by WOLFSON MEDICAL CENTER · Apr 22, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effects of two medications, dipyrone and acetaminophen, in treating fever during labor in women who may have an infection called chorioamnionitis. Chorioamnionitis is a condition that can happen during childbirth and may lead to complications for both the mother and the baby. The trial aims to find out which medication works better to lower fever quickly, as managing fever during labor is important for the health of both the mother and the baby.

Women who are 18 years or older and are going to have a vaginal delivery may be eligible to participate if they have a fever of 39°C (102.2°F) or higher, or a sustained fever of 38°C (100.4°F) for at least 30 minutes, along with other signs of possible infection. Participants in the trial will receive either dipyrone or acetaminophen and will be monitored closely for any side effects. It’s important to note that women with certain medical histories or conditions, such as liver disease or previous bad reactions to these medications, will not be included in the study. This trial could provide valuable information on how to better manage fever during labor and improve outcomes for mothers and their babies.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Women undergoing a trial of vaginal delivery, with suspected intra-amniotic infection defined as isolated maternal fever of 39°C or greater, or an sustained oral temperature of 38-38.9°C for at least 30 minutes or with one or more of the following: maternal leukocytosis, purulent cervical drainage, or fetal tachycardia.
• Exclusion Criteria:
• • Known history of adverse events for dipyrone or acetaminophen
• • Age \<18 years
• • Gestational age \<24 weeks
• • Intrauterine fetal death
• • Fever onset prior to delivery
• • Known liver disease
• • Known leukopenia
• • In addition, those who will develop allergic event or any adverse event possible related to any of the antipyretics used will be excluded from the